I learned about “timely and equitable access” to oncology drugs at the Canadian Breast Cancer Network's metastatic breast cancer advocacy training in 2013. I was the first in Canada prescribed Perjeta, days after Health Canada approved the drug. My oncologist shared exciting trial results about dual blockade (using two drugs simultaneously against breast cancer). The trastuzumab emtansine (TDM-1) trial had closed days earlier. Another combo was available but it was “back pocket.” The caveat was that it wasn’t funded but my extended health insurance benefits agreed to pay. On route to my first infusion, I penned a sign: BELIEVE. We did. I had dozens of liver and lymph mets and my liver was failing. After two rounds, I had normal liver enzymes and after three, normal tumour markers.

I was born and raised in Southern Alberta and moved to Calgary to attend university and eventually raise my family here.  I am an active senior who enjoys singing with a Calgary performing group, travelling with my husband, watching sports and movies on TV, spending time with my two daughters, who both live in Calgary, keeping in touch with my granddaughter, who now lives in Victoria, and watching my grandson grow up and enjoy his activities.

On July 19, 2011, at the age of 33, I was diagnosed with breast cancer. With a 10-month-old son, I was still glowing with the joy of motherhood—but when a lump that I had been attributing to breastfeeding challenges refused to go away, I decided to see my doctor.

The more researchers and doctors learn about cancer, the more they are beginning to understand that there isn’t one standard approach to treating it but many factors to consider to come up with the best treatment plan for each person. New research is adding to this knowledge and instead of treating a cancer based on its location in the body, clinicians are starting to personalize and improve treatments for individual patients based on genomics.

My life changed forever once I received the phone call no one wants to get early one morning in March 2015. My surgeon was on the other line with the results from my recent biopsy. The lump that was supposed to be only a pesky cyst was indeed cancerous. The surgeon further explained my diagnosis. But the only thing I heard was that I had cancer. My world felt like it was spinning out of control.

If you have had surgery for breast cancer, you are at risk for lymphedema, a chronic swelling of the arm or another body part due to build-up of fluid. (This fluid, known as lymph, transports white blood cells and cellular debris throughout the body.)  Removal of lymph nodes under the arm during breast cancer surgery or radiation therapy can cause a blockage in the lymphatic system, which causes lymphedema. It can develop shortly after your surgery or many years later.

How valuable is patient input to decision-makers and how can we work to make sure that the patient voice is really being heard? These are just some of the important questions that I and many others gathered to discuss at the annual Breast Cancer Patient Group Forum in Vienna, Austria.

Recently, I celebrated my 5-year anniversary at CBCN. The thing that has become the most evident to me over these 5 years is that every single person’s experience with breast cancer is unique. Just when I think I’ve heard every story, I meet or hear from someone new and am reminded that every person diagnosed with breast cancer in this country has their own set of experiences and challenges to overcome while dealing with their diagnosis. 

Looking back at the 4 years we have hosted our event, the Pink Ribbon Project (PRP) is always interesting, emotional and clarifying. We can see the things we have accomplished and learned but most importantly where we can grow in our work around breast cancer.

Roughly 40% of Canadian women, meaning about 3 million women, have what is known as “dense breasts.” Dense breasts are normal and common, but they also pose cancer risks and screening challenges. Breast density can have a significant impact on cancer detection and the treatment and prognosis of a diagnosed cancer. Many women in Canada are unaware of their breast density, impacting their screening and their ability to be their own breast health advocate. Why is knowing and understanding your breast density so important?

On November 3, 2011, I received a phone call while waiting in line to pick up my sons, 2 and 4, from school. On the other end of the line was my wife’s GP advising me that Kate had a rare and aggressive form of breast cancer. The ensuing months brought bewilderment, fear and anger. I struggled to find a way to express what was happening to our family and to provide care.

For some, returning to work marks an important milestone in moving forward after treatment. You’ve done it, made it through treatment and are on the other side! But returning to work comes with its challenges.

This June I had the opportunity to attend the Europa Donna Metastatic Breast Cancer Advocacy Conference in Italy. The chair of our board, Cathy, was asked to speak and I was happy to join her to share with the group the advocacy that CBCN has been doing in Canada. While most of the participants that attended were representing various organizations, it was interesting learning that many of them were also women who were living with metastatic breast cancer.

When Kim Bulpitt was diagnosed in March 2016 at age 53 with breast cancer, it wasn’t her first experience with serious illness. The Kitchener, Ontario resident was previously diagnosed in 1979 with kidney disease, in 2008 with Parkinson’s disease, and in 2012 with osteoarthritis resulting in replacement of both knees in 2014.

I had the privilege to attend the Canadian Partnership Against Cancer’s (CPAC) Conference on Optimal Approaches to Cancer Care in Canada. This was the first time that CPAC hosted this conference.  Its purpose was to explore 4 key themes to cancer control: initiatives in quality care, economics of high-quality care, improving the quality of cancer diagnosis, and overcoming inertia in the cancer system (why don’t we do what we know works?). 

In August 2015 when Tanya Figg of Coaldale, Alberta was six months pregnant with her second child, she was diagnosed with Stage III invasive mammary breast cancer.  Her immediate thought was “what did this mean for me and my family?”

If you or your child has a cancer diagnosis and you need childcare in the Greater Hamilton Area of Ontario, Olive Us Care can help.

This new non-profit can provide up to 10 hours per month of free in-home childcare for children under 12 years of age.

Because fatigue is a predominant symptom of cancer, CBCN reached out to Georden Jones for advice on managing this symptom. Georden is a doctoral student in clinical psychology at the University of Ottawa. Her thesis focuses on cancer-related fatigue, in particular on the patient's experience with this symptom and how to implement assessment and interventions programs for cancer-related fatigue. Her thesis project is ongoing and is estimated to end by 2019. If you have any questions concerning her work, please do not hesitate to contact her by email: gjone046@uottawa.ca. 

On April 24th and 25th I was pleased to attend the 2017 CADTH Symposium in Ottawa. "Value in Health Care" was the conference aim, specifically how to define it, how to measure it and how to include it in our health system. But what is CADTH?  

In 2014, Krista Dumas of Kirkland Lake, Ontario, was shocked to receive a diagnosis of metastatic breast cancer at the age of 33.  The cancer was in her liver and L5 vertebrae.